DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
A photoswitchable positive allosteric modulator to control the activation of the metabotropic glutamate receptor 5 by light
Data will be made available on request., The metabotropic glutamate receptor 5 (mGlu5) is widely expressed in the brain, where it plays an important role in synaptic plasticity, learning and memory, making it a therapeutic target of interest in various neurological disorders. In this study, we developed a photoswitchable positive allosteric modulator (PAM) of the mGlu5, as a novel tool for this clinically relevant drug target. To that aim, we used an azologisation strategy of the mGlu5 PAM agonist VU0424465 leading to the molecule azoglurax. We observed a reversible photoisomerization of azoglurax in solution with optimal wavelengths of 365 nm and 435 nm for trans to cis and cis to trans isomerization, respectively. In cell-based assays, azoglurax potentiates the agonist-induced activity of mGlu5 with a sub-micromolar potency in the dark. This potency is reduced under UV illumination. Similar to its parent molecule, azoglurax acts as an allosteric agonist of mGlu5, activating the receptor in the absence of glutamate, as demonstrated on a glutamate-insensitive mutant receptor. Docking and site-directed mutagenesis experiments also suggest that azoglurax and VU0424465 bind the same pocket. In addition, molecular dynamics on cis-azoglurax-bound mGlu5 suggests that its azoglurax cis isomer does not bind stably in the receptor, in contrast to the trans-isomer, explaining the difference of activity between the two isomers. In conclusion, azoglurax is the first mGlu5 photoswitchable PAM agonist reported to date, retaining the properties and the binding mode of its parent compound in the dark, while the insertion of an azobenzene confers light-regulated activity., The authors thank Lourdes Muñoz from SIMChem (IQAC-CSIC) for the use of analytical support and helpful discussions, Charleine Zussy and Mathieu Vitalis for helpful discussions, Ebba L. Lagerqvist for critical reading of the manuscript and the staff of Montpellier Biocampus Arpege facility for their technical help. MD simulations were performed using supercomputing resources from GENCI-TGCC France (grant A0150714630 2023-2024 to XC). This work was funded by the French National Research Agency (ANR) under the “Investissements d’avenir” program I-Site MUSE with the reference ANR-16-IDEX-0006 to AD, LG and CG, the reference ANR-17-NEU3-0001 under the frame of Neuron Cofund to RBT, AL and CG, and the reference ANR-20-CE11-019 to GL. This work was also financially supported by the Fondation pour la Recherche Médicale, grant number «MND202003011477», to IT, LG and CG and by the International Emerging Action (IEA) from the Centre National de la Recherche Scientifique (CNRS) to CG and AL, Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación, and ERDF – A way of making Europe (PID2020-120499RB-I00, and PIE-RYC2020--029485-I) to A.L. and X.R., by the Agència de Gestió d'Ajuts Universitaris i de Recerca (2021 SGR 00508) and Tecnio association (URD316) to A.L. and by the Spanish National Research Council (20228AT014) to X.R. and European Union’s Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement no. 801342 (Tecniospring INDUSTRY, TECSPR19-1-0062) and the Government of Catalonia’s Agency for Business Competitiveness (ACCIÓ) to XG-S., Peer reviewed
Proyecto:
EC / H2020 801342
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-120499RB-I00
,
AEI RYC2020-029485-I
DOI: http://hdl.handle.net/10261/394387, https://api.elsevier.com/content/abstract/scopus_id/105009514292
HANDLE: http://hdl.handle.net/10261/394387, https://api.elsevier.com/content/abstract/scopus_id/105009514292